Merck is trading 3.01% up at $146.25 after Merck and Moderna’s personalized cancer vaccine, used with Keytruda, succeeded in a Phase 3 melanoma trial.
- Merck had already announced the results and plans to present pivotal oncology data at the October 23–27 ESMO Congress.
- A healthcare-sector rally following UnitedHealth’s earnings beat may also be supportive; the trial result is the clearest company-specific catalyst.